Your email has been successfully added to our mailing list.

×
0 0.0317460317460317 0.0317460317460317 0.0317460317460317 0.0317460317460317 0.027809523809524 0.00952380952380955 0.00952380952380955
Stock impact report

Alder BioPharmaceuticals® Presents New One-Year Data for Eptinezumab from PROMISE 1 Phase 3 Trial Demonstrating Long-Term Efficacy in Episodic Migraine

ALDER BIOPHARMACEUTICALS INC (ALDR) 
Last alder biopharmaceuticals inc earnings: 8/6 04:07 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.alderbio.com/node/5806
Company Research Source: GlobeNewswire
- Data presented today at the American Headache Society (AHS) Annual Scientific Meeting demonstrate eptinezumab’s robust efficacy is further improved at one year following third and fourth quarterly infusions             - Approximately one-third of patients had no migraines, (achieved 100% reduction of migraine days) on average per month, with 300 mg of eptinezumab BOTHELL, Wash., June 29, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new one-year efficacy data from the PROMISE 1 Phase 3 clinical trial in patients with episodic migraine. The data demonstrate that patients experienced even further reductions in monthly migraine days (MMDs) following the third and fourth quarterly infusions of eptinezumab, Alder’s lead investigational product candidate for migraine prevention targeting calcitonin gene-related peptide (CGRP). Detailed Show less Read more
Impact Snapshot
Event Time:
ALDR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ALDR alerts
Opt-in for
ALDR alerts

from News Quantified
Opt-in for
ALDR alerts

from News Quantified